On Friday, Dyne Therapeutics, Inc. (NASDAQ:DYN) revealed new data from its ongoing Phase 1/2 ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 (DM1).
Dyne plans to begin a global Registrational Expansion Cohort with the potential to support a submission for U.S.…